Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Raises Nearly $9M in Two Private Financings

NEW YORK (GenomeWeb News) – Caprotec Bioanalytics announced today that it has received a total of €6 million ($8.8 million) from two rounds of private financing to support further development and marketing of the firm’s Capture Compound Mass Spectrometry technology for analyzing complex protein mixtures.
 
Investors in the two rounds included Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and private investors including Heinrich-Maria Schulte, co-founder of Evotec and owner of the Wölbern Bank in Hamburg, Germany.
 
According to Berlin-based Caprotec, the CCMS technology enables targeted isolation of proteins or protein classes directly from a complex biological sample. The captured proteins are then identified and characterized by mass spectrometry.
 
“Our platform closes a technological gap in the field of proteome analysis with its ability to be applied in both water-soluble and membrane protein mixtures,” said Caprotec CEO and Founder Hubert Köster.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.